For a long time, targeted temperature management (TTM) has been considered a
crucial neuroprotective intervention in post-cardiac arrest care. Once spontaneous
circulation returns, a cerebral ischemia-reperfusion injury may occur. This
significantly increases mortality while also contributing to deteriorating
neurological outcomes in survivors. These factors have prompted research into
therapeutic hypothermia as a means to reduce secondary brain injury. Mild
hypothermia (32–34°C) improved both survival and neurological recovery in
comatose survivors of out-of-hospital cardiac arrest, according to early randomized
controlled trials published in 2002. Consequently, hypothermia protocols were
widely adopted in international resuscitation guidelines. Nevertheless, the extent of
this benefit has since been reassessed in later large-scale studies. No discernible
difference in all-cause mortality or neurological outcomes between the groups in the
2013 trial, comparing temperature targets of 33°C and 36°C among patients, was
observed. More recently, targeted hypothermia at 33°C did not lower six-month
mortality when compared to targeted normothermia combined with active fever
prevention, according to a 2021 study. The trials also indicated a potential increase
in adverse events like arrhythmias, but didn’t find any consistent benefits in terms
of survival or neurological outcomes compared to controlled normothermia.
Overall, the growing body of research has pivoted its focus to clinical practice,
straying away from routine induction of therapeutic hypothermia and moving
towards active prevention of fever. However, there still remains uncertainty
regarding optimal temperature targets and possible advantages amongst particular
patient subgroups, thus highlighting the need for further research to improve postcardiac
arrest temperature management techniques.
Keywords: targeted temperature management, post-cardiac arrest, therapeutic
hypothermia, fever prevention, active normothermia
